Angola Ministry of Health. R. 17 de Setembro, Luanda, Angola.
World Health Organization, Angola Country Office. Condomínio Rosalinda, Edifício da ONU, Estrada Direita da Samba, Futungo de Belas, Luanda, Angola.
Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A48-A57. doi: 10.1016/j.vaccine.2023.02.035. Epub 2023 Feb 17.
After six years without any detection of poliomyelitis cases, Angola reported a case of circulating vaccine-derived poliovirus type 2 (cVDPV2) with paralysis onset date of 27 March 2019. Ultimately, 141 cVDPV2 polio cases were reported in all 18 provinces in 2019-2020, with particularly large hotspots in the south-central provinces of Luanda, Cuanza Sul, and Huambo. Most cases were reported from August to December 2019, with a peak of 15 cases in October 2019. These cases were classified into five distinct genetic emergences (emergence groups) and have ties with cases identified in 2017-2018 in the Democratic Republic of Congo. From June 2019 to July 2020, the Angola Ministry of Health and partners conducted 30 supplementary immunization activity (SIA) rounds as part of 10 campaign groups, using monovalent OPV type 2 (mOPV2). There were Sabin 2 vaccine strain detections in the environmental (sewage) samples taken after mOPV2 SIAs in each province. Following the initial response, additional cVDPV2 polio cases occurred in other provinces. However, the national surveillance system did not detect any new cVDPV2 polio cases after 9 February 2020. While reporting subpar indicator performance in epidemiological surveillance, the laboratory and environmental data as of May 2021 strongly suggest that Angola successfully interrupted transmission of cVDPV2 early in 2020. Additionally, the COVID-19 pandemic did not allow a formal Outbreak Response Assessment (OBRA). Improving the sensitivity of the surveillance system and the completeness of AFP case investigations will be vital to promptly detect and interrupt viral transmission if a new case or sewage isolate are identified in Angola or central Africa.
安哥拉在六年无脊髓灰质炎病例报告后,于 2019 年 3 月 27 日报告了 1 例循环疫苗衍生脊髓灰质炎病毒 2 型(cVDPV2)病例,该病例出现麻痹症状。2019-2020 年,18 个省份共报告了 141 例 cVDPV2 脊灰病例,其中罗安达、宽扎和万博等中南部省份疫情较为集中。多数病例发生在 2019 年 8 月至 12 月,2019 年 10 月达到高峰,15 例。这些病例分为五个不同的遗传爆发(爆发组),与 2017-2018 年在刚果民主共和国发现的病例有关。2019 年 6 月至 2020 年 7 月,安哥拉卫生部和合作伙伴开展了 30 轮补充免疫活动(SIAs),作为 10 个运动组的一部分,使用单价 OPV2 (mOPV2)。在每个省 mOPV2 SIA 后采集的环境(污水)样本中均检测到萨宾 2 疫苗株。在初始应对之后,其他省份又发生了更多的 cVDPV2 脊灰病例。然而,国家监测系统在 2020 年 9 月 9 日之后没有发现任何新的 cVDPV2 脊灰病例。尽管流行病学监测指标表现不佳,但截至 2021 年 5 月的实验室和环境数据强烈表明,安哥拉在 2020 年初成功阻断了 cVDPV2 的传播。此外,由于 COVID-19 大流行,未能进行正式的暴发应对评估(OBRA)。提高监测系统的敏感性和急性弛缓性麻痹病例调查的完整性,对于在安哥拉或中非发现新病例或污水分离株时,及时发现和阻断病毒传播至关重要。